# Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Source: https://onco.cc/trials/nct05074810/  
OnCo record `nct05074810` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sotorasib in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., active and no longer recruiting.

## Summary

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients is a phase 1/2 interventional study registered as NCT05074810 by Verastem, Inc., with 153 participants planned, started 2022-04-12 and due to reach its primary completion in 2026-06. Interventions recorded: avutometinib and sotorasib, avutometinib and sotorasib and defactinib. Conditions listed: Non Small Cell Lung Cancer, KRAS Activating Mutation. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05074810
- Phase: 1/2
- Setting: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Verastem, Inc.
- Enrolled: 153

## Sources

- ClinicalTrials.gov NCT05074810: https://clinicaltrials.gov/study/NCT05074810

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Sotorasib](https://onco.cc/drugs/sotorasib/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct05074810.json